The Lancet: Phase 3 trial reports one dose of Ad5-nCoV COVID-19 vaccine is safe and effective, including against severe disease
The Ad5-nCoV vaccine, developed in China, is 57.5% effective against symptomatic COVID-19 infection and 91.7% effective ...
Read more